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Edited by Jesus AvilaAbstract The proteolysis of b-amyloid (Ab) requires neprylisin,
an enzyme that has been shown as reduced in Alzheimers disease
(AD). We investigated whether a decrease in neprilysin levels
contributes to the accumulation of amyloid deposits not only in
AD but also in the normal aging. We analyzed neprilysin mRNA
and protein levels in cerebral cortex from 10 cognitively normal
elderly subjects with amyloid plaques (NA), 10 cases of AD, and
10 control cases free of amyloid plaques. We found a signiﬁcant
decrease in neprilysin mRNA levels in both AD and NA com-
pared to control cases. Thereby, the defect of neprilysin appears
to correlate with Ab deposition but not with degeneration and
dementia.
 2005 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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According to the amyloid cascade hypothesis, accumulation
and deposition of b-amyloid (Ab) in the brain are the major
events in Alzheimers disease (AD) [1–3]. Evidence indicates
that Ab accumulation depends on the balance between Ab
production and Ab clearance [4]. The physiological metabolite
Ab is constantly produced and removed in the brain, and it has
been demonstrated that even small decreases in its removal
lead to its deposition [5–7]. Among several proteases involved
in the proteolysis of Ab, neprilysin (NEP) appears to be the
most important enzyme. NEP is a 97 kDa plasma membrane
glycoprotein that is also known as neutral endopeptidase
(EC 3.4.24.11), enkephalinase, CD10, or as common acute
lymphoblastic leukemia antigen (CALLA) [8]. In the brain,
NEP is expressed on neuronal membranes, both pre- and
post-synaptically [9].
Previous studies indicate that NEP mRNA and protein lev-
els are lower in AD compared to non-AD cases free of amyloid
plaques, suggesting that low activity of this enzyme may con-
tribute to the pathogenesis of AD [5,10,11]. Abundant amyloid
deposits, comprised of Ab aggregates, are present in the brains
of cognitively normal aged people, in spite of little or absentAbbreviations: CTR, control cases free of amyloid deposits; NA, co-
gnitively normal elderly subjects with amyloid plaques; AD, Alzhei-
mers disease; NEP, neprilysin
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tion are not exclusive to AD but rather are proportional to
aging, and this may depend on a particular neuronal resistance
to Ab due to unknown factors, or more simply put, may derive
from the quality of the Ab accumulated.
In this study, we hypothesize that low levels of NEP may
contribute to the accumulation of amyloid deposits in AD.
We measured NEP mRNA and protein levels in the cerebral
cortex of subjects with sporadic AD and compared them
against control cases that were free of amyloid deposits
(CTR) and against cognitively normal elderly subjects with
amyloid plaques (NA).2. Materials and methods
2.1. Cases
Frozen cerebral cortex (superior frontal gyrus) samples were used
that included: 10 CTR cases free of amyloid plaques, as ascertained
by immunocytochemistry using monoclonal antibody 4G8 that recog-
nizes all Ab species (mean age at death 73 ± 9, post-mortem 7 h); 10
cases with late-onset sporadic AD (mean age at death 86 ± 10, post-
mortem 9 h, Braak stage 5) (clinical history of disease; pathological
diagnosis according to CERAD criteria; provided by the brain bank
of Case Western Reserve University, Cleveland, OH; Dr. Pierluigi
Gambetti director); and 10 NA cases (mean age at death 78 ± 10,
post-mortem 10 h, Braak stage 2). The latter subjects agreed to be neu-
ropsychologically tested every six months and to be autopsied for re-
search purposes (provided by Alzheimers Disease Research Center,
University of Kentucky, Dr. William Markesbery, director). Analysis
of the NA cases showed Ab deposits and neuroﬁbrillary pathology
only in the mesial temporal lobe. The amount of Ab deposits, semi-
quantitatively evaluated in frontal cortex sections with anti-Ab anti-
body (4G8) immunostaining, was similar in AD and NA cases.
2.2. RT-PCR analysis
Total RNA was extracted from approximately 100 mg frozen brain
sample using the TRIzol Reagent (Invitrogen). In all cases, 5 lg of total
RNAwas reverse-transcribed using random primers and the cDNAwas
ampliﬁed by the polymerase chain reaction (PCR) technique. PCR was
performed using master-mix (Fermentas Life Sciences) with 5 min of
denaturation at 95 C, followed by 38 cycles of the following: 30 s at
92 C, 1.30 min at 58 C and 1 min at 72 C. The primers used were: for-
ward 5 0-TAAGCAGCCTCAGCCGAACCTACAA-3 0 and reverse 5 0-
GACTACAGCTGCTCCACTTATCCACTCA-30 (GenBank Acces-
sion No. X07166). For mRNA quantiﬁcation, b-actin was ampliﬁed in
the same samples using the forward primer 5 0-CTCACCCTGAAG-
TACCCCATCG-3 0 and the reverse primer 5 0-CTTGCTGATCCA-
CATCTGCTGG-3 0.
2.3. Immunoprecipitation of NEP
From each brain, 400 mg of tissue was homogenized in 5 vol (w/v) of
ice-cold 10 mM Tris–HCl buﬀer (pH 8.0) containing 0.25 M sucrose
and a protease inhibitor cocktail. The homogenates were centrifuged
at 10000 rpm at 4 C for 15 min and the supernatants were further cen-
trifuged at 45000 rpm at 4 C for 20 min. The pellets were solubilizedblished by Elsevier B.V. All rights reserved.
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solubilized membranes were again centrifuged at 45000 rpm at 4 C for
20 min [9]. The supernatants, used as the membrane fraction, were
immunoprecipitated overnight at 4 C with 15 ll of monoclonal anti-
human CD-10 antibody (Santa-Cruz Biotechnology, Inc.).
2.4. Western blot and protein quantiﬁcation
Immunoprecipitated proteins were resolved on 8% SDS–PAGE gels,
transferred to PVDF membranes (Amersham Biosciences), and probed
with anti-NEP antibody (Santa-Cruz Biotechnology, Inc.) and with
anti-HNE antibodies HNEJ-2 (Japan Institute for the Control of
Aging), HNE11-S (Alpha Diagnostic) and HNE-pyrrole [13]. Signals
were detected with ECL (Amersham Biosciences). The speciﬁc
97 kDa band was measured with densitometric analysis using Quantity
One software system (Biorad). Absolute values for NEP were calcu-
lated for each immunoprecipitated sample with the Lowry protein as-
say kit (BioRad) and normalized to mg of proteins.
2.5. Statistical analysis
All data were analyzed using the one-way ANOVA with Bonfer-
ronis Multiple Comparison Test as the post-test with GraphPad Prism
software. Data are presented as means ± S.E. of the three groups of
cases (CTR, NA, AD).3. Results
Expression of NEP was analyzed using RT-PCR in cerebral
cortex tissue samples taken from 10 CTR, 10 NA, and 10 AD
cases. TheNEPmRNA level was normalized to the correspond-
ing amount of actinmRNA.RelativeRT-PCRwasperformed in
triplicate and the data of the three experiments was statistically
analyzed. The levels of mRNA were signiﬁcantly decreased
(\\P < 0.01) in the NA cases (0.48 ± 0.07) and the AD cases
(0.50 ± 0.1) compared to CTR cases (0.86 ± 0.2) (Fig. 1).
In the same tissues, NEP was immunoprecipitated with anti-
NEP antibody and Western blot analysis was performed using
anti-NEP and anti-HNE antibodies. The anti-NEP antibody
detected a band migrating at 97 kDa, as predicted for NEP.
The quantiﬁcation analysis revealed a lower level of NEP pro-
tein in the NA (0.043 ± 0.03) and AD (0.045 ± 0.01) cases inFig. 1. Total mRNA levels for neprilysin in frontal cortex of CTR, NA and
ﬁve representative cases for each group. (B) Histograms represent neprilysin
of actin mRNA. Data are expressed as mean values ± SEM of three diﬀerencomparison to the CTR cases (0.050 ± 0.05), but without
revealing a signiﬁcant diﬀerence among the three groups
(Fig. 2). The 97 kDa band did not show any HNE reactivity
with the three diﬀerent anti-HNE antibodies in all cases exam-
ined (data not shown).4. Discussion
The overproduction of Ab, or the failure to remove it, is a
complex process which leads to the formation of amyloid pla-
ques and to the development of Alzheimers disease [2–4]. Re-
cent ﬁndings indicate that NEP plays a key role in decreasing
the levels of cerebral Ab deposition. Several studies have
shown that in vitro overexpression of NEP signiﬁcantly de-
creases Ab levels [7,14]. Moreover, downregulation of NEP
promoted Ab deposition in the brain of transgenic mice [15–
17] and the role of NEP in reducing Ab accumulation was also
demonstrated in transgenic mice overexpressing human nepri-
lysin [18]. In agreement with these ﬁndings, Yasojima et al. [10]
reported that NEP mRNA and protein levels were reduced by
50% and 70% in AD patients, respectively, compared to aged-
matched controls.
The present study aimed to extend these ﬁndings by includ-
ing cognitively normal elderly cases with abundant Ab deposits
and scarce neuroﬁbrillary pathology (NA individuals). The
normal elderly subjects that we considered diﬀered from AD
not in the amount but in the quality of Ab species, arguing that
AD is pathogenetically a distinct disease and not an acceler-
ated form of aging [19].
We observed that NEP mRNA levels in cerebral cortex were
signiﬁcantly lower in both NA and AD groups compared to
subjects free of amyloid deposits. NEP protein levels were also
lower in NA and AD cases compared to the amyloid-free
cases, although without signiﬁcant diﬀerence. This discrepancy
could be due to reduced protein degradation or to an increased
eﬃciency of mRNA transcription and might be compensated
by analyzing larger groups of cases.AD cases. (A) RT-PCR data for neprilysin and corresponding actin in
mRNA levels for all 30 cases, normalized to the corresponding amount
t experiments for each group (\\P < 0.01).
Fig. 2. Total neprilysin protein levels from CTR, NA and AD cases. (A) A speciﬁc protein band (97 kDa) was revealed with anti-NEP antibody in
ﬁve representative cases for each group. (B) Histograms indicate the densitometric analysis of neprilysin western blot bands normalized to the
corresponding total protein for all 30 cases.
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presence of amyloid plaques and not with cognitive dysfunc-
tion. Therefore, the decrease in NEP levels, observed also in
NA subjects, indicates that this event is not a peculiarity of
AD, and that diﬀerent mechanisms are responsible for the neu-
ronal dysfunction and degeneration observed in AD. For exam-
ple, the harmless amyloid deposition seen in NA could depend
on a particular neuronal resistance to Ab due to unknown fac-
tors, or more simply, may derive from the quality of the accu-
mulated Ab [19,20]. Furthermore, several other mechanisms
besides the toxic eﬀect of Ab are putatively involved in the path-
ogenesis of AD [21,22]. Wang et al. [23] suggest that NEP activ-
ity is impaired in AD because the protein is partially altered by
oxidation. In our cases presented here, we did not ﬁnd oxidized
NEP in either the AD or normal brains, as demonstrated by the
absence of HNE reactivity in the extracted NEP.
In contrast from our ﬁndings, Wang et al. [24] reported a de-
crease in NEP immunoreactivity in their AD cases compared
to ‘‘pathological aging’’. The subjects that were selected for
this study were cognitively normal, as demonstrated by neuro-
psychological tests, and their neocortex was absolutely free of
neuroﬁbrillary pathology. It is possible, then, that the patho-
logical aging cases analyzed by Wang et al. and our NA cases
substantially diﬀer in the extent of neurodegeneration, thus
accounting for the contrasting results.
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